AzTrials
AzTrials

Molar Incisor HypomineralizationECLIPSENCT07653373

Effect of Enamel Cleaning on a Remineralizing Paste for Hypomineralizated Lesions

A study testing Sodium hypochlorite 5.25% and CPP-ACPF in people with Molar Incisor Hypomineralization, run by Universidade Ceuma at 1 site in Brazil.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Molar-incisor hypomineralization (MIH) is a qualitative defect of dental enamel, in which low mineral content and high protein content compromise the effectiveness of remineralizing treatments. Various agents have been used to remove proteins from hypomineralized enamel, such as sodium hypochlorite (NaOCl). Read more about this study

Who is it for?
Ages 7 to 9 yearsHealthy volunteers can take part
Conditions the study is for
Molar Incisor Hypomineralization
What is being tested?
Sodium hypochlorite 5.25% and CPP-ACPF
Could I receive a placebo?
No, everyone receives an active treatment
How many people
54 participants
Where
1 siteBrazil
Study dates
Aug 2026to Apr 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 to 9 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Children with at least one permanent molar without MIH.
  • At least two permanent molars with mild MIH lesions (demarcated opacities without structural loss)
  • Lesions may be with or without sensitivity
  • Lesions cream-white or yellowish in color
  • Lesions ≥ 2 mm in diameter
  • Lesions may be on the same or different dental arches

Who cannot join

  • Visible bacterial biofilm
  • Enamel malformations associated with syndromes
  • Amelogenesis imperfecta
  • Fluorosis
  • Allergy to milk proteins (casein)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Meire C. Ferreira, PhD contact

+5598988955888

meirecofe@hotmail.com

Nicole P. Veras, PhD contact

05598983088600

npaivaveras@gmail.com

Brazil1 site
  • Universidade Ceuma

    São Luís, Maranhão, 65075-120

Other trials in Brazil

About this study

Official title: The Effect Of Deproteinization On The Performance Of CPP-ACPF On Hypomineralized Enamel: A Clinical Evaluation

Molar-incisor hypomineralization (MIH) is a qualitative defect of dental enamel, in which low mineral content and high protein content compromise the effectiveness of remineralizing treatments. Various agents have been used to remove proteins from hypomineralized enamel, such as sodium hypochlorite (NaOCl). Sodium hypochlorite is an antimicrobial irrigant capable of dissolving tissues. The amorphous calcium fluoride casein phosphate phosphopeptide (CPP-ACPF) is used as a remineralizing agent for MIH lesions, it is capable of stabilizing calcium, phosphate, and fluoride ions on the tooth surface, maintaining them in an amorphous form. Therefore, the objective of this study is to evaluate the clinical performance of CPP-ACPF dental mousse on deproteinized hypomineralized enamel.

Read the detailed description

MIH is characterized by a marked opacity, asymmetrically involving the first permanent molars and incisors. In more severe cases of MIH, in addition to the retention of matrix proteins that should have been removed during the enamel maturation process, its more porous structure allows the penetration of proteins present in saliva, which bind to the poorly developed hydroxyapatite crystals. The high protein content of enamel with MIH also promotes the growth of proteolytic bacteria, posing a challenge for the adhesion of restorative materials and treatments for hypersensitivity. Some products containing CPP-ACPF have been used in children with MIH, it can stabilize calcium, phosphate, and fluoride ions on the tooth surface. Given that MIH lesions have a high protein content that may prevent the mineralizing agent from reaching the underdeveloped enamel prisms, it is expected that treatment with CPP-ACPF will be more effective following prior deproteinization of the affected enamel. A double-blind, split-mouth, randomized clinical trial will be conducted. The teeth included in the study will be permanent upper or lower molars with MIH in children aged 7 to 9 years. Two properly calibrated examiners will select the participants, and the diagnosis of MIH lesions will be based on the criteria of the European Association of Paediatric Dentistry (EAPD). The inclusion criteria will be: one permanent molar without MIH; at least two permanent molars with mild MIH lesions (demarcated opacities without structural loss), with or without sensitivity, of a cream-white or yellowish color, and 2 mm in diameter; and without visible bacterial biofilm. The selected teeth from each participant will be divided into 3 groups: Control Group (molars without hypomineralization); CPP-ACPF Group (hypomineralized molars treated with CPP-ACPF); and NaOCl/CPP-ACPF Group (hypomineralized molars deproteinized with 5.25% NaOCl, with application time based on laboratory study findings, and treated with CPP-ACPF). The randomization of treatments for hypomineralized teeth will be performed at the time of treatment. The following data collection tools will be used: a questionnaire to collect demographic and socioeconomic information, as well as information on etiological factors for MIH; clinical examination to assess the following aspects of the lesions: location (occlusal or middle third), lesion area (in mm²), color (cream-white or yellowish), visual appearance (shiny or opaque), sensitivity, and lightness of the lesion color (L). The tooth's L will be measured three times to obtain the average of the values. The data will be analyzed descriptively and inferentially. Clinical analyses will include intragroup comparisons (between follow-up times) and intergroup comparisons (between group outcomes), at a 5% significance level.

Being tested
Sodium hypochlorite 5.25%, CPP-ACPF
Keywords
molar hypomineralization, dental enamel, spectrophotometry, dental remineralization
Medical subject headings
Molar Hypomineralization

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sodium hypochlorite 5.25%Drug

    Also called NaOCL

    Sodium hypochlorite is a proteolytic substance that interferes with the cellular metabolism of proteins.

  • CPP-ACPFDrug

    Also called Amorphous calcium fluoride casein phosphate phosphopeptide

    Casein is a milk-derived protein that, during enzymatic digestion in the mouth, is converted into a casein phosphopeptide (CPP) molecule. CPP is capable of stabilizing calcium, phosphate, and fluoride ions on the tooth surface, keeping them in an amorphous form. Thus, CPP-ACPF functions as a reservoir of calcium phosphate.

Study groups in NCT07653373
Study groupRoleWhat they receive
Control Group (molars without hypomineralization)No interventionHealth molars without hypomineralization
CPP-ACPF in hypomineralized molarsExperimentalHypomineralized molars treated with CPP-ACPF, without prior deproteinization. (Treatment will be administered once a week for 4 consecutive weeks).
Receives: Drug: CPP-ACPF
Sodium hypochlorite 5.25%/CPP-ACPF GroupExperimentalHypomineralized molars treated with CPP-ACPF, with preliminary deproteinization (Treatment will be administered once a week for 4 consecutive weeks)
Receives: Drug: Sodium hypochlorite 5.25%; Drug: CPP-ACPF

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mineralization of MIH lesions

    The measurements will be taken using a spectrophotometer (Vita Easyshade) to assess tooth brightness before and after treatment

    Measured: 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jun 2026
  2. Study startAug 2026 (estimated)
  3. Primary completionDec 2027 (estimated)
  4. Study completionApr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
54 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07653373
Sponsor's protocol ID
UnCeuma
Acronym
ECLIPSE
Status last verified
Jul 2026
First submitted
11 Jun 2026
Last updated
8 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Sonmez H, Saat S. A Clinical Evaluation of Deproteinization and Different Cavity Designs on Resin Restoration Performance in MIH-Affected Molars: Two-Year Results. J Clin Pediatr Dent. 2017;41(5):336-342. doi: 10.17796/1053-4628-41.5.336.

    PubMed 28872993
  • Mangum JE, Crombie FA, Kilpatrick N, Manton DJ, Hubbard MJ. Surface integrity governs the proteome of hypomineralized enamel. J Dent Res. 2010 Oct;89(10):1160-5. doi: 10.1177/0022034510375824. Epub 2010 Jul 22.

    PubMed 20651090
  • Mahoney E, Ismail FS, Kilpatrick N, Swain M. Mechanical properties across hypomineralized/hypoplastic enamel of first permanent molar teeth. Eur J Oral Sci. 2004 Dec;112(6):497-502. doi: 10.1111/j.1600-0722.2004.00162.x.

    PubMed 15560832
  • Gandhi S, Crawford P, Shellis P. The use of a 'bleach-etch-seal' deproteinization technique on MIH affected enamel. Int J Paediatr Dent. 2012 Nov;22(6):427-34. doi: 10.1111/j.1365-263X.2011.01212.x. Epub 2012 Jan 18.

    PubMed 22251382
  • Bullio Fragelli CM, Jeremias F, Feltrin de Souza J, Paschoal MA, de Cassia Loiola Cordeiro R, Santos-Pinto L. Longitudinal Evaluation of the Structural Integrity of Teeth Affected by Molar Incisor Hypomineralisation. Caries Res. 2015;49(4):378-83. doi: 10.1159/000380858. Epub 2015 May 13.

    PubMed 25998233
  • Fagrell TG, Dietz W, Jalevik B, Noren JG. Chemical, mechanical and morphological properties of hypomineralized enamel of permanent first molars. Acta Odontol Scand. 2010 Jul;68(4):215-22. doi: 10.3109/00016351003752395.

    PubMed 20392131
  • Elhennawy K, Manton DJ, Crombie F, Zaslansky P, Radlanski RJ, Jost-Brinkmann PG, Schwendicke F. Structural, mechanical and chemical evaluation of molar-incisor hypomineralization-affected enamel: A systematic review. Arch Oral Biol. 2017 Nov;83:272-281. doi: 10.1016/j.archoralbio.2017.08.008. Epub 2017 Aug 19.

    PubMed 28843745
  • Crombie FA, Cochrane NJ, Manton DJ, Palamara JE, Reynolds EC. Mineralisation of developmentally hypomineralised human enamel in vitro. Caries Res. 2013;47(3):259-63. doi: 10.1159/000346134. Epub 2013 Jan 29.

    PubMed 23363890
  • Americano GC, Jacobsen PE, Soviero VM, Haubek D. A systematic review on the association between molar incisor hypomineralization and dental caries. Int J Paediatr Dent. 2017 Jan;27(1):11-21. doi: 10.1111/ipd.12233. Epub 2016 Apr 21.

    PubMed 27098755
  • Amend S, Stork S, Lucker S, Seipp A, Gartner U, Frankenberger R, Kramer N. Influence of different pre-treatments on the resin infiltration depth into enamel of teeth affected by molar-incisor hypomineralization (MIH). Dent Mater. 2024 Jul;40(7):1015-1024. doi: 10.1016/j.dental.2024.05.010. Epub 2024 May 13.

    PubMed 38744567
  • Altan H, Yilmaz RE. Clinical evaluation of resin infiltration treatment masking effect on hypomineralised enamel surfaces. BMC Oral Health. 2023 Jul 3;23(1):444. doi: 10.1186/s12903-023-03140-6.

    PubMed 37400849
  • Olgen IC, Sonmez H, Bezgin T. Effects of different remineralization agents on MIH defects: a randomized clinical study. Clin Oral Investig. 2022 Mar;26(3):3227-3238. doi: 10.1007/s00784-021-04305-9. Epub 2021 Nov 25.

    PubMed 34821978
  • Kumar A, Goyal A, Gauba K, Kapur A, Singh SK, Mehta SK. An evaluation of remineralised MIH using CPP-ACP and fluoride varnish: An in-situ and in-vitro study. Eur Arch Paediatr Dent. 2022 Feb;23(1):79-87. doi: 10.1007/s40368-021-00630-5. Epub 2021 May 31.

    PubMed 34057698

Questions about this trial

What is this clinical trial studying?

A study testing Sodium hypochlorite 5.25% and CPP-ACPF in people with Molar Incisor Hypomineralization, run by Universidade Ceuma at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Meire C. Ferreira, PhD (+5598988955888, meirecofe@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mineralization of MIH lesions (time frame: 1 month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07653373, which also lists 13 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in